Atenolol: Difference between revisions
ClaireLewis (talk | contribs) |
(modified dosage form, added dosage strength/routes of administration) |
||
(10 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: [[Beta blocker]] | *Type: [[Beta blocker]] | ||
*Dosage Forms: PO | *Dosage Forms: tablet | ||
*Dosage Strengths: 25, 50, 100mg | |||
*Routes of Administration: PO | |||
*Common Trade Names: Tenormin | *Common Trade Names: Tenormin | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Hypertension]]=== | ===[[Hypertension]]=== | ||
*50- | *50-100mg PO QD, Start 50mg PO QD | ||
*Max: | *Max: 100mg/day | ||
===[[ | ===[[Stable angina]]=== | ||
*50- | *50-200mg PO QD, Start 50mg PO QD | ||
*Max: | *Max: 200mg/day | ||
===Cardiovascular event prevention, post-MI=== | ===Cardiovascular event prevention, post-MI=== | ||
* | *100mg/day PO divided QD-bid | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===[[Hypertension]]=== | ===[[Hypertension]]=== | ||
*1- | *1-2mg/kg PO QD, Start 0.8-1mg/kg PO QD | ||
*Max: | *Max: 2mg/kg/day | ||
===[[Supraventricular arrhythmias]]=== | ===[[Supraventricular arrhythmias]]=== | ||
*0.3- | *0.3-2mg/kg PO QD | ||
*Max: | *Max: 2mg/kg/day | ||
==Special Populations== | ==Special Populations== | ||
Line 29: | Line 31: | ||
*Lactation: Possibly unsafe | *Lactation: Possibly unsafe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult: CrCl 10-50: | **Adult: CrCl 10-50: decrease dose 50%, give q48h, max 50mg/day; CrCl<10: decrease dose 50-70%, give q96h, max 25mg/day; HD: give dose after dialysis, no supplement; PD: no supplement | ||
**Pediatric: CrCl 30-50: max | **Pediatric: CrCl 30-50: max 1mg/kg up to 50mg q24h; CrCl<30: max 1mg/kg up to 25mg q24h or up to 50mg q48h; HD: give dose after dialysis, no supplement; PD: no supplement | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult: not defined | **Adult: not defined | ||
Line 59: | Line 61: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*CHF | *[[CHF]] | ||
*[[bradycardia]], severe | *[[bradycardia]], severe | ||
*heart block | *heart block | ||
*angina exacerbation if abrupt discontinuation | *angina exacerbation if abrupt discontinuation | ||
* | *[[Myocardial infarction]] if abrupt discontinuation | ||
*ventricular arrhythmia during treatment and if abruptly discontinue | *ventricular arrhythmia during treatment and if abruptly discontinue | ||
*Raynaud phenomenon | *Raynaud phenomenon | ||
Line 95: | Line 97: | ||
==See Also== | ==See Also== | ||
==References== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] |
Revision as of 20:25, 11 October 2017
General
- Type: Beta blocker
- Dosage Forms: tablet
- Dosage Strengths: 25, 50, 100mg
- Routes of Administration: PO
- Common Trade Names: Tenormin
Adult Dosing
Hypertension
- 50-100mg PO QD, Start 50mg PO QD
- Max: 100mg/day
Stable angina
- 50-200mg PO QD, Start 50mg PO QD
- Max: 200mg/day
Cardiovascular event prevention, post-MI
- 100mg/day PO divided QD-bid
Pediatric Dosing
Hypertension
- 1-2mg/kg PO QD, Start 0.8-1mg/kg PO QD
- Max: 2mg/kg/day
Supraventricular arrhythmias
- 0.3-2mg/kg PO QD
- Max: 2mg/kg/day
Special Populations
- Pregnancy Rating: D
- Lactation: Possibly unsafe
- Renal Dosing
- Adult: CrCl 10-50: decrease dose 50%, give q48h, max 50mg/day; CrCl<10: decrease dose 50-70%, give q96h, max 25mg/day; HD: give dose after dialysis, no supplement; PD: no supplement
- Pediatric: CrCl 30-50: max 1mg/kg up to 50mg q24h; CrCl<30: max 1mg/kg up to 25mg q24h or up to 50mg q48h; HD: give dose after dialysis, no supplement; PD: no supplement
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- sinus bradycardia
- 2nd or 3rd degree AV block
- heart failure, uncompensated
- cardiogenic shock
- sick sinus syndrome with out pacemaker
- pheochromocytoma, untreated
- avoid abrupt withdrawal
- caution if peripheral vascular disease
- caution if bronchospastic disease
- caution if major surgery
- caution if diabetes mellitus
- caution if thyroid disorder
- caution if WPW syndrome
- caution if renal impairment
- caution if pregnancy
- caution if breastfeeding
- caution if myasthenia gravis
- caution if severe anaphylactic reaction history
- caution in elderly patients
Adverse Reactions
Serious
- CHF
- bradycardia, severe
- heart block
- angina exacerbation if abrupt discontinuation
- Myocardial infarction if abrupt discontinuation
- ventricular arrhythmia during treatment and if abruptly discontinue
- Raynaud phenomenon
- bronchospasm
- hypersensitivity reaction
- lupus erythematosus
Common
- bradycardia
- hypotension
- fatigue
- dizziness
- cold extremities
- depression
- dyspnea
- hypotension, orthostatic
- leg pain
- bronchospasm
- lightheadedness
- lethargy
- diarrhea
- nausea
- vertigo
- drowsiness
Pharmacology
- Half-life: 6-7h
- Metabolism: CYP450
- Excretion: urine 40-50%, feces 50%
- Mechanism of Action: selectively antagonizes beta-1 adrenergic receptors